SEVCIKOVA, Tereza, Katerina GROWKOVA, Zuzana CHYRA, Jana FILIPOVA, P. VRUBLOVA, Tomas JELINEK, Z. KORISTEK, F. KRYUKOV, Elena Vladimirovna KRYUKOVA and Roman HÁJEK. Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies. Journal of clinical pathology. London: BMJ Publishing Group, 2017, vol. 70, No 10, p. 847-853. ISSN 0021-9746. Available from: https://dx.doi.org/10.1136/jclinpath-2017-204329.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Biobanking strategy and sample preprocessing for integrative research in monoclonal gammopathies
Authors SEVCIKOVA, Tereza (203 Czech Republic), Katerina GROWKOVA (203 Czech Republic), Zuzana CHYRA (203 Czech Republic, belonging to the institution), Jana FILIPOVA (203 Czech Republic), P. VRUBLOVA (203 Czech Republic), Tomas JELINEK (203 Czech Republic), Z. KORISTEK (203 Czech Republic), F. KRYUKOV (203 Czech Republic), Elena Vladimirovna KRYUKOVA (203 Czech Republic, guarantor, belonging to the institution) and Roman HÁJEK (203 Czech Republic).
Edition Journal of clinical pathology, London, BMJ Publishing Group, 2017, 0021-9746.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30109 Pathology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW Full Text
Impact factor Impact factor: 2.894
RIV identification code RIV/00216224:14110/17:00100122
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1136/jclinpath-2017-204329
UT WoS 000411180200006
Keywords in English monoclonal gammopathies; MULTIPLE-MYELOMA; BONE-MARROW; PLASMA-CELLS; CRITERIA; DISEASE; RNA
Tags NZ, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Marie Šípková, DiS., učo 437722. Changed: 2/1/2020 16:21.
Abstract
Aims Some types of monoclonal gammopathies are typified by a very limited availability of aberrant cells. Modern research use high throughput technologies and an integrated approach for detailed characterisation of abnormal cells. This strategy requires relatively high amounts of starting material which cannot be obtained from every diagnosis without causing inconvenience to the patient. The aim of this methodological paper is to reflect our long experience with laboratory work and describe the best protocols for sample collection, sorting and further preprocessing in terms of the available number of cells and intended downstream application in monoclonal gammopathies research. Potential pitfalls are also discussed. Methods Comparison and optimisation of freezing and sorting protocols for plasma cells in monoclonal gammopathies, followed by testing of various nucleic acid isolation and amplification techniques to establish a guideline for sample processing in haemato-oncology research. Results We show the average numbers of aberrant cells that can be obtained from various monoclonal gammopathies (monoclonal gammopathy of undetermined significance/light chain amyloidosis/multiple myeloma (MM)/MM circulating plasma cells/minimal residual disease MM-10 123/22 846/305 501/68 641/4000 aberrant plasma cells of 48/30/10/16/37x106 bone marrow mononuclear cells) and the expected yield of nucleic acids provided from multiple isolation kits (DNA/RNA yield from 1 to 200x10(3) cells was 2.14-427/0.12-123 ng). Conclusions Tested kits for parallel isolation deliver outputs comparable with kits specialised for just one type of molecule. We also present our positive experience with the whole genome amplification method, which can serve as a very powerful tool to gain complex information from a very small cell population.
PrintDisplayed: 27/4/2024 06:59